[1] Neijenhuis M K, Kievit W, Verheesen S M, et al. Impact of liver volume on polycystic liver disease-related symptoms and quality of life [J]. United European Gastroenterology J, 2018, 6(1): 81-88.
[2] Cowles R A, Mulholland M W. Solitary hepatic cysts [J]. J Am Coll Surg , 2000, 191(3): 311-321.
[3] Bean W J, Rodan B A. Hepatic cysts: treatment with alcohol [J]. AJR Am J Roentgenol, 1985, 144(2): 237-241.
[4] 王顺义, 宋书邦, 张玉英. 849例肝包虫囊肿超声引导下穿刺硬化治疗的疗效评价 [J]. 中华医学超声杂志:电子版, 2011, 8(7):4.
[5] Miquel L, Preaubert L, Gnisci A, et al. Endometrioma ethanol sclerotherapy could increase IVF live birth rate in women with moderate-severe endometriosis [J]. PLoS One, 2020, 15(9): e0239846.
[6] Zhang H, Xiong S H, Jiang X J, et al. A painless and time-saving modified technique for simple renal cyst treatment with single-session ethanol sclerotherapy [J]. Sci Rep, 2020, 10(1): 5019.
[7] Wijnands T F, Görtjes A P, Gevers T J, et al. Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review [J]. AJR Am J Roentgenol, 2017, 208(1): 201-207.
[8] 张琼, 陈士颖, 夏维. 超声引导下无水乙醇与聚桂醇硬化治疗单纯性肝囊肿患者效果比较研究 [J]. 实用肝脏病杂志, 2023, 26(3): 428-431.
[9] 夏天祥. 新型硬化剂聚桂醇与无水乙醇治疗单纯性肝囊肿临床疗效的对比研究 [D]. 蚌埠医学院,2021.
[10] 长蒙. 超声引导下无水乙醇与聚桂醇硬化治疗较大单纯性肝囊肿的临床疗效对比分析[J].世界华人消化杂志, 2018, 26(24):7.
[11] Danza F M, Falcione M, Bordonaro V, et al. Minocycline hydrochloride as a soft sclerotizing agent for symptomatic simple renal and hepatic cysts [J]. Eur Rev Med Pharmacol Sci, 2017, 21(2): 408-415.
[12] Furumaya A, Van rosmalen B V, De graeff J J, et al. Systematic review on percutaneous aspiration and sclerotherapy versus surgery in symptomatic simple hepatic cysts [J]. HPB (Oxford), 2021, 23(1): 11-24.
[13] Z'graggen K, Metzger A, Klaiber C. Symptomatic simple cysts of the liver: treatment by laparoscopic surgery [J]. Surg Endosc, 1991, 5(4): 224-225.
[14] Tartaglia N, Di lascia A, Cianci P, et al. Surgical management of non-parasitic hepatic cysts A single center experience and a review of the literature [J]. Ann Ital Chir, 2019, 90:514-519.
[15] Hartmann K D, mortensen F V. Surgical treatment of symptomatic simple liver cysts [J]. Dan Med J, 2022, 70(1): A08220469.
[16] Bernts L H P, Echternach S G, Kievit W, et al. Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis [J]. Surg Endosc, 2019, 33(3): 691-704.
[17] Gomez A, Wisneski A D, Luu H Y, et al. Contemporary management of hepatic cyst disease: techniques and outcomes at a tertiary hepatobiliary center [J]. J Gastrointest Surg, 2021, 25(1): 77-84.
[18] Wu Z, Chen Y, Jin Y, et al. Application of pedicled greater omentum flap tamponade combined with laparoscopic fenestration in diaphragmatic hepatic cyst [J]. BMC Surg, 2022, 22(1): 369.
[19] Yang F, Qian Z, Sun F, et al. Laparoscopic enucleation of hepatic cysts reduces the recurrence of nonparasitic hepatic cysts [J]. J Laparoendosc Adv Surg Tech A, 2021, 31(3): 314-319.
[20] Vardakostas D, Damaskos C, Garmpis N, et al. Minimally invasive management of hepatic cysts: indications and complications [J]. Eur Rev Med Pharmacol Sci, 2018, 22(5): 1387-1396.
[21] Une N, Fujio A, Mitsugashira H, et al. Laparoscopic liver cyst fenestration with real-time indocyanine green fluorescence-guided surgery: a case report [J]. J Surg Case Rep, 2021, 2021(5): rjab196.
[22] 李宏伟, 底卫东, 张瑞, 等. 腹腔镜开窗引流术治疗单纯性肝囊肿的临床评价 [J]. 腹腔镜外科杂志, 2015, 20(3): 205-207.
[23] Chen C, Zhang R, Wan R. Novel technique for treating simple hepatic cysts: endoscopic transgastric hepatic cyst deroofing [J]. Endoscopy, 2022, 54(S 02): E1045-E1046.
[24] Kinoshita S, Nishizawa T, Tojo M, et al. Simple drainage versus drainage with minocycline infusion for symptomatic hepatic cysts [J]. J Clin Biochem Nutr, 2023, 72(1): 89-91.
[25] Van aerts R M M, Van de laarschot L F M, Banales J M, et al. Clinical management of polycystic liver disease [J]. J Hepatol, 2018, 68(4): 827-837.
[26] Gigot J F, Jadoul P, Que F, et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? [J]. Ann Surg, 1997, 225(3): 286-294.
[27] Aussilhou B, Dokmak S, Dondero F, et al. Treatment of polycystic liver disease. Update on the management [J]. J Visc Surg, 2018, 155(6): 471-481.
[28] Norcia L F, Watanabe E M, Hasimoto C N, et al. Effectiveness of open fenestration for autosomal dominant polycystic liver disease [J]. Case Rep Gastroenterol, 2022, 16(1): 201-208.
[29] Zhang Z Y, Wang Z M, Huang Y. Polycystic liver disease: classification, diagnosis, treatment process, and clinical management [J]. World J Hepatol, 2020, 12(3): 72-83.
[30] Li A Y, Bergquist J R, August A T, et al. Laparoscopic hepatic lobectomy for symptomatic polycystic liver disease [J]. HPB (Oxford), 2021, 23(1): 56-62.
[31] Zhang Z, Hu K, Yang J, et al. Severe polycystic liver diseases: hepatectomy or waiting for liver transplantation?: Two case reports [J]. Medicine (Baltimore), 2019, 98(49): e18176.
[32] Smith T W Jr, Goldberg A, Lu A D. Preserving the organ donor pool and suprahepatic vena cava: case series of transverse hepatectomy for polycystic liver disease [J]. Ann Hepatol, 2021, 20:100118.
[33] Bernts L H P, Neijenhuis M K, Edwards M E, et al. Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease [J]. Surgery, 2020, 168(1): 25-32.
[34] Sakuhara Y, Nishio S, Hattanda F, et al. Initial experience with the use of tris-acryl gelatin microspheres for transcatheter arterial embolization for enlarged polycystic liver [J]. Clin Exp Nephrol, 2019, 23(6): 825-833.
[35] Zhang J L, Yuan K, Wang M Q, et al. Transarterial embolization for treatment of symptomatic polycystic liver disease: more than 2-year follow-up [J]. Chin Med J (Engl), 2017, 130(16): 1938-1944.
[36] Coussy A, Jambon E, Le Bras Y, et al. The safety and efficacy of hepatic transarterial embolization using microspheres and microcoils in patients with symptomatic polycystic liver disease [J]. J Pers Med, 2022, 12(10):1624.
[37] Yan J Y, Zhang J L, Yuan K, et al. Transarterial embolisation with bleomycin and N-butyl-2-cyanoacrylate-Lipiodol mixture for symptomatic polycystic liver disease: preliminary experience [J]. Clin Radiol, 2019, 74(12): 975.
[38] Alsager M, Neong S F, Gandhi R, et al. Liver transplantation in adult polycystic liver disease: the Ontario experience [J]. BMC Gastroenterol, 2021, 21(1): 115.
[39] Ding F, Tang H, Zhao H, et al. Long-term results of liver transplantation for polycystic liver disease: single-center experience in China [J]. Exp Ther Med, 2019, 17(5): 4183-4189.
[40] Dios-Barbeito S, Domínguez-Bastante M, Moreno-Navas A, et al. Multicentric study of the andalusian experience in polycystic liver disease as indication for liver transplantation [J]. Transplant Proc, 2018, 50(2): 613-616.
[41] Ogawa K, Fukunaga K, Takeuchi T, et al. Current treatment status of polycystic liver disease in Japan [J]. Hepatol Res, 2014, 44(11): 1110-1118.
[42] Serrano Rodriguez P, Barritt A I, Gerber D A, et al. Liver transplant for unusually large polycystic liver disease: challenges and pitfalls [J]. Case Rep Transplant, 2018, 2018:4863187.
[43] Suwabe T, Barrera F J, Rodriguez-Gutierrez R, et al. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials [J]. Plos One, 2021, 16(9): e0257606.
[44] Yoo J J, Jo H I, Jung E A, et al. Evidence of nonsurgical treatment for polycystic liver disease [J]. Ther Adv Chronic Dis, 2022, 13:20406223221112563.
[45] Hogan M C, Chamberlin J A, Vaughan L E, et al. Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial [J]. Clin J Am Soc Nephrol, 2020, 15(9): 1267-1278.
[46] Lorenzo Pisarello M, Masyuk T V, Gradilone S A, et al. Combination of a histone deacetylase 6 inhibitor and a somatostatin receptor agonist synergistically reduces hepatorenal cystogenesis in an animal model of polycystic liver disease [J]. Am J Pathol, 2018, 188(4): 981-994.
[47] Van Aerts R M M, Bernts L H P, GEVERS T J G, et al. Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients [J]. Clin Pharmacol Ther, 2019, 106(6): 1338-1345.
[48] Duijzer R, Barten T R M, Staring C B, et al. Treatment of polycystic liver disease: impact on patient-reported symptom severity and health-related quality of life [J]. J Clin Gastroenterol, 2022, 56(9): 731-739. |
